Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CVS Health Corporation stock logo
CVS
CVS Health
$75.00
+0.4%
$67.11
$43.56
$75.55
$95.10B0.626.81 million shs6.40 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$23.51
-7.4%
$28.34
$23.15
$75.37
$9.15B1.9310.85 million shs31.22 million shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CVS Health Corporation stock logo
CVS
CVS Health
0.00%+1.68%+12.33%+11.24%+33.67%
Moderna, Inc. stock logo
MRNA
Moderna
0.00%-6.48%-11.91%-11.85%-70.43%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CVS Health Corporation stock logo
CVS
CVS Health
$75.00
+0.4%
$67.11
$43.56
$75.55
$95.10B0.626.81 million shs6.40 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$23.51
-7.4%
$28.34
$23.15
$75.37
$9.15B1.9310.85 million shs31.22 million shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CVS Health Corporation stock logo
CVS
CVS Health
0.00%+1.68%+12.33%+11.24%+33.67%
Moderna, Inc. stock logo
MRNA
Moderna
0.00%-6.48%-11.91%-11.85%-70.43%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CVS Health Corporation stock logo
CVS
CVS Health
2.96
Moderate Buy$77.893.86% Upside
Moderna, Inc. stock logo
MRNA
Moderna
2.05
Hold$41.8177.85% Upside

Current Analyst Ratings Breakdown

Latest MRNA and CVS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/8/2025
CVS Health Corporation stock logo
CVS
CVS Health
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-BuyHold
9/5/2025
CVS Health Corporation stock logo
CVS
CVS Health
Sanford C. Bernstein
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetMarket Perform$72.00 ➝ $77.00
9/4/2025
CVS Health Corporation stock logo
CVS
CVS Health
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$80.00 ➝ $87.00
8/26/2025
CVS Health Corporation stock logo
CVS
CVS Health
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$78.00
8/22/2025
Moderna, Inc. stock logo
MRNA
Moderna
Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetUnderperform$18.00 ➝ $15.00
8/18/2025
CVS Health Corporation stock logo
CVS
CVS Health
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeNeutralBuy$67.00 ➝ $79.00
8/14/2025
CVS Health Corporation stock logo
CVS
CVS Health
Baird R W
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHoldStrong-Buy
8/14/2025
CVS Health Corporation stock logo
CVS
CVS Health
Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeNeutralOutperform$71.00 ➝ $82.00
8/4/2025
CVS Health Corporation stock logo
CVS
CVS Health
Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/4/2025
Moderna, Inc. stock logo
MRNA
Moderna
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetEqual Weight$40.00 ➝ $31.00
8/1/2025
Moderna, Inc. stock logo
MRNA
Moderna
Evercore ISI
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$32.00
(Data available from 9/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CVS Health Corporation stock logo
CVS
CVS Health
$372.81B0.26$9.09 per share8.25$60.18 per share1.25
Moderna, Inc. stock logo
MRNA
Moderna
$3.24B2.83N/AN/A$28.33 per share0.83
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CVS Health Corporation stock logo
CVS
CVS Health
$4.61B$3.5820.9511.080.831.17%10.51%3.15%11/5/2025 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
-$3.56B-$7.53N/AN/AN/A-94.31%-25.96%-20.09%11/6/2025 (Estimated)

Latest MRNA and CVS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/1/2025Q2 2025
Moderna, Inc. stock logo
MRNA
Moderna
-$2.99-$2.13+$0.86-$2.13$116.26 million$142.00 million
7/31/2025Q2 2025
CVS Health Corporation stock logo
CVS
CVS Health
$1.46$1.81+$0.35$0.80$94.87 billion$98.92 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
CVS Health Corporation stock logo
CVS
CVS Health
$2.663.55%N/A74.30%4 Years
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A

Latest MRNA and CVS Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/7/2025
CVS Health Corporation stock logo
CVS
CVS Health
quarterly$0.66503.99%7/22/20257/22/20258/1/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CVS Health Corporation stock logo
CVS
CVS Health
0.74
0.80
0.62
Moderna, Inc. stock logo
MRNA
Moderna
N/A
3.93
3.77

Institutional Ownership

CompanyInstitutional Ownership
CVS Health Corporation stock logo
CVS
CVS Health
80.66%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%

Insider Ownership

CompanyInsider Ownership
CVS Health Corporation stock logo
CVS
CVS Health
1.22%
Moderna, Inc. stock logo
MRNA
Moderna
11.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
CVS Health Corporation stock logo
CVS
CVS Health
300,0001.27 billion1.25 billionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
5,800389.08 million346.28 millionOptionable

Recent News About These Companies

Moderna (NASDAQ:MRNA) Shares Down 5.6% - Time to Sell?
Sept. consumer sentiment falls, Moderna & COVID report, Gemini IPO
Why Moderna (MRNA) Shares Are Trading Lower Today
Bullish flow in Moderna with shares up 4.13%
Why Moderna (MRNA) Shares Are Falling Today
Moderna, Inc. $MRNA Position Increased by Amundi

New MarketBeat Followers Over Time

Media Sentiment Over Time

CVS Health stock logo

CVS Health NYSE:CVS

$75.00 +0.33 (+0.44%)
Closing price 09/12/2025 03:59 PM Eastern
Extended Trading
$74.84 -0.16 (-0.21%)
As of 09/12/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates. The Health Services segment offers pharmacy benefit management solutions, including plan design and administration, formulary management, retail pharmacy network management, specialty and mail order pharmacy, clinical, disease management, and medical spend management services. It serves employers, insurance companies, unions, government employee groups, health plans, prescription drug plans, Medicaid managed care plans, CMS, plans offered on public health insurance, and other sponsors of health benefit plans. The Pharmacy & Consumer Wellness segment sells prescription and over-the-counter drugs, consumer health and beauty products, and personal care products. This segment also distributes prescription drugs; and provides related pharmacy consulting and other ancillary services to care facilities and other care settings. It operates online retail pharmacy websites, LTC pharmacies and on-site pharmacies, retail specialty pharmacy stores, compounding pharmacies and branches for infusion and enteral nutrition services. The company was formerly known as CVS Caremark Corporation and changed its name to CVS Health Corporation in September 2014. CVS Health Corporation was incorporated in 1996 and is headquartered in Woonsocket, Rhode Island.

Moderna stock logo

Moderna NASDAQ:MRNA

$23.51 -1.88 (-7.40%)
Closing price 09/12/2025 04:00 PM Eastern
Extended Trading
$23.64 +0.13 (+0.57%)
As of 09/12/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.